Earnings OutlookConvatec still expects margin expansion in FY25 to 22.0-22.5%, and to deliver double-digit adjusted EPS growth, both in-line or slightly ahead of expectations.
Financial PerformanceFY24 results are at the top end of guidance and expectations, with 7.7% organic revenue growth the best since IPO.
Regulatory ClarityThe postponement of the LCDs relating to Skin Substitute Grafts/Cellular and Tissue-Based Products by the CMS removes, at least for now, the uncertainty regarding the potential long-term impact on InnovaMatrix and alleviates any market concern regarding the LCDs' effect on the company's growth trajectory.